Navigation Links
Concentric Medical Completes Enrollment in Prospective Multi Center Stentriever™ Trial for Mechanical Thrombectomy in Stroke
Date:9/8/2011

MOUNTAIN VIEW, Calif., Sept. 8, 2011 /PRNewswire/ -- Concentric Medical, Inc., a global leader in acute ischemic stroke intervention, today announced completion of enrollment of the TREVO Study.  The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first evaluation of Stentriever™ technology in a European, multicenter, prospective clinical trial.  The TREVO Study was designed to assess the ability of the Trevo® System to remove the blood clots that cause strokes and to restore blood flow to the brain.

The TREVO Study employed the latest generation of the Trevo® Retrieval System and the preliminary results are very promising. Interim data from the study were presented in May at the European Stroke Congress by Professor Olav Jansen, Head of Neuroradiology at Universitatsklinikum Schleswig-Holstein Kiel.  The interim revascularization rate in the first 36 patients was 96%. Thirty patients had 90-day follow up and 63% of these had a good outcome.  A "good outcome" was defined as being functionally independent at 90 days (modified Rankin score of 2 or less).

Professor Olav Jansen and Professor Nils Wahlgren, Professor of Neurology at Karolinska University Hospital, are co-Principal Investigators of the Study. Professor Wahlgren commented: "The TREVO study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes for these patients."

"The Trevo System is the first device of this type designed specifically for removal of the clot in ischemic stroke patients.  Not only was it easy to use, but the architectural properties of the device enhance clot integration into the device, making the procedures fast and remarkably effective," commented Juan Macho, MD, PhD of Hospital Clinic Barcelona.

Maria Sainz, President and CEO of Concentric Medical, commented on the importance of the study: "Clinical evidence remains key for wider adoption of interventional device-based therapies for acute ischemic stroke patients. The prospective design of the TREVO Study continues to support Concentric Medical's commitment to building robust evidence for our technologies for physicians and their stroke patients. This is an important milestone which supports the clinical efficacy of the Trevo Retrieval System. We sincerely thank all of our Principal Investigators and all other investigators for their commitment and passion in completing this significant study."

About Concentric Medical

Concentric Medical is located in Mountain View, California and is a global leader in the development of endovascular devices for revascularizing stroke patients. Concentric Medical's devices are available in over 500 leading stroke centers around the world, and have been the subject of several clinical studies.

For more information about Concentric Medical, please visit www.concentric-medical.com.

About the Trevo System

The Trevo System is an innovative, high-performing, easy-to-use thrombus retrieval system. The main component of the Trevo System is the Trevo Retriever which introduces Stentriever™ technology, creating a new generation of retrieval devices to remove clots in acute stroke patients.  Concentric Medical is the pioneer in developing devices for ischemic stroke intervention. Since 2002, Concentric Medical's devices have been used in thousands of stroke patients worldwide. This experience has been incorporated into the design of the Trevo System to make thrombus removal an easier, faster and more predictable procedure.   The new Trevo System combined with the Merci®Retriever, DAC® (Distal Access Catheters) and Balloon Guide Catheter portfolio of products further strengthens Concentric Medical's position as a global leader in acute ischemic stroke intervention.  

About Acute Ischemic Stroke

Stroke is one of the leading causes of death in the developed world and the leading cause of serious long-term disability. Ischemic stroke represents over 85% of strokes and occurs when a blockage or clot develops in one of the arteries supplying blood to the brain.

Media Contact:
+1 650-938-2100
strokeinfo@concentric-medical.com


'/>"/>
SOURCE Concentric Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concentric Medical to Sponsor Randomized Trial
2. Concentric Medical and the Merci Retrieval System(R) Highlighted at the 2010 International Stroke Conference
3. Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
4. Concentric Medical Announces Commercial Launch of Trevo™ in Europe
5. Concentric Medical Announces First Stroke Patients Treated in Canada with Trevo™ System
6. Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial
7. Concentric Medical Launches Full Family of Merci Retrievers® in Japan
8. Concentric Medical Launches DAC® 070, A New Distal Access Catheter
9. STRYKER Signs Definitive Agreement to Acquire CONCENTRIC MEDICAL, Inc.
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):